High antineoplastic activity of new heterocyclic compounds in cancer cells with resistance against classical DNA topoisomerase II‐targeting drugs
Open Access
- 17 April 2006
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 119 (1), 213-220
- https://doi.org/10.1002/ijc.21792
Abstract
Twenty previously synthesized fused heterocyclic DNA-topoisomerase II (Topo II)-inhibiting compounds were investigated for their potential efficacy in various human cancer cell lines that were derived from different tumor entities. Moreover, different multidrug-resistant variants of these cancer cell lines with decreased Topo II expression were investigated. In parental, drug-sensitive cells merely the compounds BD3 and G35 showed efficacies, in terms of μM, which were similar to that of the classical Topo II inhibitor etoposide. On the other hand, most of the tested heterocyclic compounds were found more effective in drug-resistant cells than in the parental, drug-sensitive ones, and some of the compounds showed high antineoplastic efficacy in several drug-resistant cell models. Compounds BD13, BD14 and BD16 exhibited high antineoplastic activities against the drug-resistant sublines EPG85-257RNOV and EPG85-257RDB derived from gastric carcinoma, EPP85-181RNOV and EPP85-181RDB derived from pancreatic carcinoma, MCF-7/Adr derived from breast cancer, D79/86RNOV derived from fibrosarcoma, and MeWoETO1 derived from melanoma. Furthermore, compound D23 was found highly efficient in the multidrug-resistant variants HT-29RNOV and HT-29RDB derived from colon carcinoma, and compound D24 exhibited the highest antineoplastic activity among the tested compounds in the drug-resistant subline MDA-MB-231ROV derived from breast cancer. In conclusion, compounds BD 13, BD 14, BD 16, D 23 and D 24 may be useful for the treatment of different multidrug-resistant cancer cells with cross resistance against “classical” Topo II-targeting drugs.Keywords
This publication has 30 references indexed in Scilit:
- Reversal of different drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDR1/P-gp, MRP2, and BCRPMolecular Therapy, 2005
- Synthesis and Antimicrobial Activity of New 2‐[p‐Substituted‐benzyl]‐5‐[substituted‐carbonylamino]benzoxazolesArchiv der Pharmazie, 2004
- Some fused heterocyclic compounds as eukaryotic topoisomerase II inhibitorsBiochemical and Biophysical Research Communications, 2004
- Glypican-3 is involved in cellular protection against mitoxantrone in gastric carcinoma cellsOncogene, 2003
- Topoisomerase II inhibitorsPublished by Elsevier BV ,2003
- Multiple mechanisms confer different drug-resistant phenotypes in pancreatic carcinoma cellsZeitschrift für Krebsforschung und Klinische Onkologie, 2002
- Cytotoxic signalling by inhibitors of DNA topoisomerase IIBiochemical Society Transactions, 2001
- Synthesis and microbiological activity of some N-(o-hydroxyphenyl)benzamides and phenylacetamides as the possible metabolites of antimicrobial active benzoxazoles: part IIIl Farmaco, 2000
- Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26Biochemistry, 1988
- STUDIES ON THE PROPAGATION IN VITRO OF POLIOMYELITIS VIRUSESThe Journal of Experimental Medicine, 1953